Stocks in play: Crescita Therapeutics Inc.

Has signed an exclusive commercialization and supply agreement with Egis Pharmaceuticals PLC, a leading generic pharmaceutical company in Central Eastern Europe for the rights to Pliaglisin eight countries comprising: Hungary, Bulgaria, Czech Republic, Slovakia, Poland, Russia, Latvia and Lithuania. Crescita Therapeutics Inc. shares T.CTX are trading unchanged at $0.58.

Read:

• Oncology Drug Developers Looking at Significant Projected Growth Through 2030

• Plant-Based Meats Continue to Sprout Growing Revenues on Year-Over-Year Basis

• No Apparent Need to Panic Over Omicron as Vaccine Developers Are on the Case

• Plant-Based Meats Market Projected to Hit $162 Billion by 2030, as New Products Launch

• Innovations in Plant-Based Protein Products Supplying the Food Industry’s Strongest Trends